Time‐dependent biomarker accuracy in forecasting mild cognitive impairment

Overall, our results delineate a timeline of the accuracy provided by different biomarkers for predicting progression to MCI. Such findings highlight the dynamic sensitivity of different biomarkers, which is dependent on the time lapse between biomarkers collection and clinical diagnosis. This is particularly relevant for future clinical trials that intend to use biomarkers for screening participants.